A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Cancer metastases; Malignant melanoma; Renal cancer
- Focus Therapeutic Use
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Apr 2007 New trial record.